Source-grounded facts extracted from PAVmed Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PAVmed Inc. reported first quarter ended March 31, 2026 results: net income approximately $7.0 million, EPS $(4.42) per common share on a diluted basis.
“On May 15, 2026, PAVmed Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2026”
PAVmed Inc. reported financial results for year ended December 31, 2025.
“PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results”
PAVmed Inc. reported three months ended December 31, 2025 results: net income approximately $1.8 million, EPS $(2.05) per common share on a diluted basis.
“For the three months ended December 31, 2025, Operating expenses were approximately $6.9 million which include stock-based compensation expenses of $0.3 million. GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.”
PAVmed Inc.: Approved amendment to certificate of incorporation to permit removal of directors with or without cause by majority vote (effective 2026-03-27).
“A certificate of amendment reflecting the amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on March 27, 2026 and became effective on such date.”
PAVmed Inc. issued warrants (the “ Warrant ”) to purchase an additional 30,000 shares of Series D Preferred Stock of warrant to certain accredited investors for $100,000 of its investment.
“with certain accredited investors (the “ Investors ”) and, pursuant to and concurrently with the execution of the Subscription Agreements, sold to the Investors, for an aggregate purchase price of $30 million, (i) 30,000 shares of the Company’s newly designated Series D Convertible Preferred Stock, par value $0.001 per share (the “ Series D Preferred Stock ”), and (ii) warrants (the “ Warrant ”) to purchase an additional 30,000 shares of Series D Preferred Stock, with each investor receiving 100 shares of Series D Preferred Stock and a warrant to purchase 100 shares of Series D Preferred Stock for each $100,000 of its investment”
PAVmed Inc. issued 30,000 shares of the Company's newly designated Series D Convertible Preferred Stock of preferred stock to certain accredited investors for aggregate purchase price of $30 million.
“On February 3, 2026, PAVmed Inc. (the “ Company ”) entered into subscription agreements (the “ Subscription Agreements ”) with certain accredited investors (the “ Investors ”) and, pursuant to and concurrently with the execution of the Subscription Agreements, sold to the Investors, for an aggregate purchase price of $30 million, (i) 30,000 shares of the Company’s newly designated Series D Convertible Preferred Stock”
PAVmed Inc. amended Amended and Restated 2022 Note (the "2026 Note") with the Holder valued at $15 million principal amount (effective 2026-02-03).
“Concurrently with the Offering, the Company redeemed all 16,962 shares of Series C Preferred Stock outstanding and refinanced all $8,414,890 in principal and interest of its Senior Secured Convertible Note issued in September (the “ 2022 Note ”), in consideration of a cash payment to the holder thereof (the “ Holder ”) of approximately $22,346,241 (which was made using proceeds from the sale of the Series D Preferred Stock), and the issuance to the Holder of an amended and restated 2022 Note (the “ 2026 Note ”) with a principal amount of $15 million.”
PAVmed Inc. entered into Subscription Agreements with certain accredited investors valued at $30 million aggregate purchase price (effective 2026-02-03).
“On February 3, 2026, PAVmed Inc. (the “ Company ”) entered into subscription agreements (the “ Subscription Agreements ”) with certain accredited investors (the “ Investors ”) and, pursuant to and concurrently with the execution of the Subscription Agreements, sold to the Investors, for an aggregate purchase price of $30 million, (i) 30,000 shares of the Company’s newly designated Series D Convertible Preferred Stock, par value $0.001 per share (the “ Series D Preferred Stock ”), and (ii) warrants (the “ Warrant ”) to purchase an additional 30,000 shares of Series D Preferred Stock, with each investor receiving 100 shares of Series D Preferred Stock and a warrant to purchase 100 shares of Series D Preferred Stock for each $100,000 of its investment (the “ Offering ”).”
PAVmed Inc. issued common stock.
“it will conduct a 1-for-30 reverse stock split of its common stock (the “Common Stock”). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time.”
PAVmed Inc.: Certificate of amendment to effect a 1-for-30 reverse stock split and reduce authorized common stock from 250,000,000 to 25,000,000 shares (effective 2026-01-02).
“the Company filed a certificate of amendment to its certificate of incorporation, as amended, pursuant to which the Reverse Split and the Reduction in Authorized Common Stock will become effective on Friday, January 2, 2026, at 12:01 a.m. Eastern Time”
PAVmed Inc. engaged CBIZ CPAs P.C. as its auditor.
“on April 23, 2025, solely as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of PAVmed Inc. (the " Company ") and, with the approval of the audit committee of the Company’s board of directors, CBIZ CPAs was engaged as the Company’s independent registered public accounting firm on the same date.”
Marcum LLP resigned as auditor of PAVmed Inc..
“on April 23, 2025, solely as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of PAVmed Inc. (the " Company ") and, with the approval of the audit committee of the Company’s board of directors, CBIZ CPAs was engaged as the Company’s independent registered public accounting firm on the same date.”
PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through January 22, 2025), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that the Company would be afforded 180 calendar days (until July 22, 2025) to regain compliance. In order to regain compliance, the closin”
PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J”
PAVmed Inc.: Information incorporated by reference from Item 3.02; no substantive change described.
“The information set forth and incorporated by reference under Item 3.02 is incorporated under this item by reference.”
PAVmed Inc.: Amendment to increase authorized common stock from 50 million to 250 million shares (effective 2025-01-15).
“A proposal to approve an amendment to the Company’s certificate of incorporation, as amended (the “ Certificate of Incorporation ”), to increase the total number of shares of common stock the Company is authorized to issue by 200,000,000 shares, from 50,000,000 shares to 250,000,000 shares.”
Sundeep Agrawal, M.D. was appointed as Class B Director at PAVmed Inc..
“the Company’s board of directors appointed Sundeep Agrawal, M.D. as a Class B director.”
Joan B. Harvey resigned as Director at PAVmed Inc..
“James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.”
James L. Cox, M.D. resigned as Director at PAVmed Inc..
“James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.”
PAVmed Inc. reported three months ended March 31, 2024 results: revenue $1.0 million, net income $22.8 million, EPS $(2.62) per common share.
“well in furtherance of this revised strategy.” Highlights from the first quarter and recent weeks include : ● Yesterday, Lucid reported that 1Q24 EsoGuard ® revenue was $1.0 million, which was flat compared to 4Q23 and represents a 124 percent increase from 1Q23. ● Strengthened balance sheet by Lucid’s completion of a $29.8 million Series B Preferred Stock”
PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at approximately $11.6 million (effective 2024-05-01).
“entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors (collectively, the “ Investors ”), which agreements provided for the sale to the Investors of approximately 11,634 shares of Lucid Diagnostics’ newly designated Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share (collectively, the “ Offering ”). The gross proceeds to Lucid Diagnostics of the Offering were approximately $11.6 million.”
PAVmed Inc. entered into Registration Rights Agreement with Series B Investors (effective 2024-03-13).
“Lucid Diagnostics and the Series B Investors also executed a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable pursuant to the Series B Preferred Stock.”
PAVmed Inc. entered into Exchange Agreement with certain accredited investors valued at 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (effective 2024-03-13).
“On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share, and (ii) the exchange by the Series B Investors of 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), and 10,670 shares of Lucid Diagnostics’ Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), held by them for 31,790 shares of Series B Prefe”
PAVmed Inc. entered into Series B Subscription Agreement with certain accredited investors valued at 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value (effective 2024-03-13).
“On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share”
PAVmed Inc. amended Amendment and Waiver with holder of senior secured convertible notes valued at $2,000,000 cash payment; maturity extended to April 4, 2025 (April 2022 Note) and September 8, 2025 (effective 2024-03-12).
“Effective as of March 12, 2024, PAVmed Inc. (the “ Company ”), entered into an amendment and waiver (the “ Amendment and Waiver ”) with the holder of the senior secured convertible note issued by the Company as of April 4, 2022 (the “ April 2022 Note ”) and the secured convertible note issued by the Company as of September 8, 2022 (the “ September 2022 Note ,” and together with the April 2022 Note, the “ Notes ”).”
PAVmed Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“March 7, 2024, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) stating that, for the last 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities (“ MVLS ”) had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The notification letter stated that the Company would be afforded 180 calendar days (until September 3, 2024) to regain compliance. In order to regain compliance, the C”
PAVmed Inc.: Filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split, reducing the authorized common shares from 250,000,000 to 50,000,000 (effective 2023-12-07).
“On December 5, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “ Charter Amendment ”) with the Secretary of State of the State of Delaware, pursuant to which, effective at 12:01 a.m. Eastern Time on December 7, 2023, the Reverse Split will be effected.”
PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at aggregate gross proceeds to Lucid of $5.0 million (effective 2023-10-17).
“Effective as of October 17, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors for the sale of 5,000 shares of newly designated Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), at a purchase price of $1,000 per share, for aggregate gross proceeds to Lucid of $5.0 million”
PAVmed Inc. shareholders approved Ratification of appointment of Marcum LLP as independent registered certified public accounting firm for year ending December 31, 2023 at the 2023-06-21 meeting.
“For Against Abstain Broker Non-Votes 62,544,780 402,955 135,729 —”
PAVmed Inc. shareholders rejected Approval of amendment to certificate of incorporation to incorporate new Delaware law provisions regarding officer exculpation at the 2023-06-21 meeting.
“For Against Abstain Broker Non-Votes 22,962,343 1,211,939 358,693 38,550,489”
PAVmed Inc. shareholders approved Election of two Class A directors: Ronald M. Sparks and Timothy Baxter at the 2023-06-21 meeting.
“For Authority Withheld Broker Non-Votes Ronald M. Sparks 21,571,438 2,961,537 38,550,489 Timothy Baxter 22,077,090 2,455,885 38,550,489”
PAVmed Inc. shareholders approved A proposal to approve an amendment to the certificate of incorporation to effect a reverse stock split and an associated reduction in authorized shares at the 2023-03-31 meeting.
“Stockholders representing approximately 70.8% of the shares outstanding and entitled to vote were present in person or by proxy. At the Special Meeting, the stockholders approved the sole proposal presented.”
PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at $13.625 million (effective 2023-03-07).
“On March 7, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ” or the “ Company ”) entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors for the sale of 13,625 shares of newly designated Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), at a purchase price of $1,000 per share, for aggregate gross proceeds to the Company of $13.625 million, in a private placement (the “ Preferred Offering ”).”
PAVmed Inc. terminated Management Services Agreement with ResearchDx, Inc. valued at Termination reduces earnout and management fees from $3,450,000 to $725,000, resulting in net saving (effective 2023-02-10).
“On February 14, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), and LucidDx Labs Inc. (“LucidDx Labs”), a wholly owned subsidiary of Lucid Diagnostics, entered into an agreement (the “ Termination Agreement ”) with ResearchDx, Inc. (“ RDx ”), pursuant to which the parties mutually agreed to terminate the Management Services Agreement, dated as of February 25, 2022, by and between LucidDx Labs and RDx (the “ MSA ”), without cause. The termination was effective as February 10, 2023.”
PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 29, 2022, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through December 28, 2022), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that the Company would be afforded 180 calendar days (until June 27, 2023) to regain compliance. In order to regain compliance, the clos”
PAVmed Inc. reported the three months ended September 30, 2022 results: revenue $0.1 million, net income approximately $26.2 million, EPS $(0.29) per common share.
“For the three months ended September 30, 2022, EsoGuard related revenues were $0.1 million. Operating expenses were approximately $23.4 million, which include stock-based compensation expenses of $4.8 million. GAAP net loss attributable to common stockholders was approximately $26.2 million, or $(0.29) per common share.”
Shaun O’Neil was appointed as Chief Operating Officer at PAVmed Inc..
“On February 22, 2022, the board of directors (the “Board”) of PAVmed Inc. (the “Company”) appointed Shaun O’Neil as the Company’s Chief Operating Officer.”
Joan B. Harvey was appointed as Class C director at PAVmed Inc..
“Effective February 11, 2022, the board of directors of PAVmed Inc. (the “ Company ”) appointed Joan B. Harvey as a Class C director of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.